Share

Contacts

  • Hans Arwidsson

    CEO


    Nanna Svarts väg 4 17165 Solna
    +46706340171
    +46706340171
    http://www.eurocine-vaccines.com
  • Quotes

    It is exciting times for us when both protein and mRNA-based vaccines may be combined in our portfolio, proving our thorough and broad experience.
    Dr Hans Arwidsson, CEO Eurocine Vaccines
    It is extremely satisfying to see the rapid and precise work with transferring our know-how in this development project.
    Sandra Jeldes Granstrand, Director of CMC Development, Eurocine Vaccines
    Biovian, our selected CDMO, has proven their scientific and technical ability in this area of biologic process development and GMP manufacturing.
    Sandra Jeldes Granstrand, Director of CMC Development, Eurocine Vaccines
    We have reached an important milestone by generating the research cell bank for the work to come. Now, the extensive work with developing a quality assured manufacturing process and thorough documentation has begun.
    Soile Tuomela, Project Manager at Biovian
    My team and I are thrilled to work at the frontier of advanced drug development with the experts of Eurocine Vaccines.
    Soile Tuomela, Project Manager at Biovian
    By optimizing the vaccine candidate, we can focus the immune response so that the antibodies formed bind to relevant parts of the chlamydia bacterium to an even greater extent than before. This is probably of great importance for how effective the vaccine is, which will be studied in future studies.
    Dr. Karl Ljungberg, Director of Preclinical Development
    Now we will move forward with the vaccine candidate and evaluate both the immune response of T cells and protection against infection and disease. It will be very exciting to see to what extent the immune response is converted into protection.
    Dr. Karl Ljungberg, Director of Preclinical Development
    The results confirm that we are on the right track with the vaccine and support the strategy we have chosen for the development - to already at this stage invest in the development of a manufacturing method, suitable for manufacturing on an industrial scale.
    Dr. Hans Arwidsson, CEO
    This confirmation is an important step ahead of further development of the chlamydia vaccine candidate towards the first clinical study.
    Dr. Hans Arwidsson, CEO
    It has been an incredibly exciting period for Eurocine Vaccines and we have managed to close very important agreements.
    CEO Hans Arwidsson
    Both we and Biovian are looking forward to the collaboration and the mutual knowledge transfer within biological pharmaceutical production, which is a highly intense area in the development of new pharmaceuticals.
    CEO Hans Arwidsson
    The selection of Biovian means that we can conduct our activities with continuity, since they also have their own GMP facility for the manufacture of products for clinical studies.
    CEO Hans Arwidsson
    The evaluation agreement reaffirms the great interest in our vaccine technology Endocine™ and gives Eurocine Vaccines increased visibility in the global market. The veterinary market for vaccines represents large and worldwide sales and can thus be a significant complement to human vaccines, which are the main focus of Eurocine Vaccines.
    Dr. Hans Arwidsson, CEO
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe